- Home
- NPCT vs EVMN Comparison
NPCT vs EVMN Comparison
Compare NPCT & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
BUY
Current Price
$5.17
Company Overview
Basic Information| Metric | NPCT | EVMN |
|---|---|---|
| Founded | 2020 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.7M | 241.3M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | NPCT | EVMN |
|---|---|---|
| Price | $8.96 | $5.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 95.3K | ★ 841.0K |
| Earning Date | 01-01-0001 | 11-07-2026 |
| Dividend Yield | ★ 9.82% | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $8.86 | $5.64 |
| 52 Week High | $10.82 | $33.20 |
Technical Indicators
Market Signals| Indicator | NPCT | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 29.68 | 17.76 |
| Support Level | N/A | N/A |
| Resistance Level | $9.90 | $13.35 |
| Average True Range (ATR) | 0.14 | 0.46 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 19.15 | 4.29 |
Price Performance
Historical Comparison NPCT
EVMN
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.